ατοπικη δερματιτιδα

download ατοπικη δερματιτιδα

of 9

  • date post

    30-Jul-2015
  • Category

    Healthcare

  • view

    208
  • download

    1

Embed Size (px)

Transcript of ατοπικη δερματιτιδα

1. H (), , , , . .. , 10- 15%, . , 1 5 65% 85% . ( 1). . , , , , , (/), , ( 1). A , , , / (xerosis). , , . . , , , . , , (IgE) , , , . , , . , , , , , , 50% , . A 2. A , . 90% . , , . . IgE , . , IgE- 2 6 . A . 5 5%. , , 30% - 40%, 80%, IgE , (). , . , ., ' . H . 4 : (1) , (2) , , (3) , (4) , . . . 3. . . A (, ..) . . (340C ) 10 min . PH . , . , . H (, , ) , . . , , . 150-200 500 . . , , . , 40 - 50 . , . , , , , , . ( , ) ( ). , - - . , . 4 - . ( 2). 4. 4 1800 . . , . , , , . , , . 15/ 10/ . , ( ) . (T) A. - . 2 : tacrolimus ( 0,03% 0,1%) pimecrolimus 1% . A. >10 / >15 / / >15gr / >30gr/ (tacrolimus, pimecrolimus) . T , , .. , . , , ( ) . , FDA T, o , . , - . T 15 , , . (proactive treatment). H ( 12 ) , 5. ( 3 ). . A. , . , . (. ) . , , , . ( ) , . , . ( ) . , A . A. . . A S aureus. , , S aureus, . , , , , . , , , . S aureus (MRSA) A . , 6. , . , . . , MRSA . MRSA . A, . 0,005% 120 mL (1/2 ) 5% ( 120 lt) . 1ml 5% . 15 lt 15ml . 5-10 2-3 . . , , Coxsackie 6 " coxsackieum". . . , . A : 1) 2) . , . . , . . - / , 7. references Al Shobaili HA. The impact of childhood atopic dermatitis on the patients family. Pediatr Dermatol . 2010;27(6):618623 Brenninkmeijer EE, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol . 2009;26(1):1422 Chisolm SS, Taylor SL, Balkrishnan R, Feldman SR. Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol . 2008;59(4):677683 Dohil MA, Eichenfield LF. A treatment approach for atopic dermatitis. Pediatr Ann . 2005;34(3):201210 Elias PM, Steinhoff M. Outside-to-inside (and now back to outside) pathogenic mechanisms in atopic dermatitis. J Invest Dermatol . 2008;128(5):10671070 Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol . 2014;70(2):338351 Horii KA, Simon SD, Liu DY, Sharma V. Atopic dermatitis in children in the United States, 1997- 2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics . 2007;120(3). Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics . 2008;122(4):812824 Moore K, David TJ, Murray CS, Child F, Arkwright PD. Effect of childhood eczema and asthma on parental sleep and well-being: a prospective comparative study. Br J Dermatol . 2006;154(3):514518 Ring J, Mhrenschlager M, Henkel V. The US FDA black box warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf . 2008;31(3):185198 Rork JF, Sheehan WJ, Gaffin JM, et al. Parental response to written eczema action plans in children with eczema. Arch Dermatol . 2012;148(3):391392 Simonsen AB, Deleuran M, Johansen JD, Sommerlund M. Contact allergy and allergic contact dermatitis in children - a review of current data. Contact Dermat . 2011;65(5):254265 Wahn U, Bos JD, Goodfield M, et al., Flare Reduction in Eczema with Elidel (Children) Multicenter 8. Investigator Study Group. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics . 2002;110(1 pt 1) T 1 T (>3 ) IgE : , 1 9. 32 / 1 2